● BREAKING NEWS
HealthBiz
search
Menu
Hospitals Nov 07, 2026 · min read

Dr Agarwal's Q2 FY27 Profit Jumps 55.8% on 27.9% Margin

₹57 crore of profit on ₹665 crore of revenue is a thin slice — 8.5%. But that slice grew 55.8% in a year, and the operating business underneath it is running at...

Team HealthBiz

HealthBiz

Dr Agarwal's Q2 FY27 Profit Jumps 55.8% on 27.9% Margin

Dr Agarwal's Health Care reported ₹665 crore in Q2 FY27 revenue with EBITDA of ₹186 crore, up 28.8% year on year at a 27.9% margin. Profit after tax rose 55.8% to ₹57 crore — an 8.5% net margin — meaning operating gains amplified into a much larger percentage jump in net profit. The takeaway: the operating engine is healthy, but the thin bottom line is the constraint investors should watch, not the headline growth number.

Key Facts
**Main Update
** Revenue for Q2 FY27 stood at ₹665 crore; EBITDA ₹186 crore, up 28.8% YoY, at a 27.9% margin.
**Profit
** PAT grew 55.8% YoY to ₹57 crore, translating to an 8.5% PAT margin.
**Margin Gap
** Roughly ₹129 crore separates EBITDA from PAT — absorbed by depreciation, finance costs and tax.
**Impact
** Profit growth of 55.8% is nearly double the 28.8% EBITDA growth, indicating operating leverage on a small base.
**Official Response
** No management commentary, guidance or segment breakdown was available in the material reviewed; figures are as disclosed.
**Current Status
** Reported quarterly numbers only — revenue growth rate, same-store performance and debt levels were not part of the disclosed data.

₹57 crore of profit on ₹665 crore of revenue is a thin slice — 8.5%. But that slice grew 55.8% in a year, and the operating business underneath it is running at a 27.9% margin. For Dr Agarwal's Health Care, the Q2 FY27 numbers say something more interesting than "profit up": an eye-care chain is converting scale into operating leverage, even as the money left at the bottom of the P&L stays unusually small.

The results put revenue at ₹665 crore and EBITDA at ₹186 crore, up 28.8% year on year. Profit after tax climbed to ₹57 crore. What follows is what those numbers actually mean — for the business, for patients walking into its centres, and for anyone holding the stock.

₹665 Crore Revenue, ₹186 Crore EBITDA: Reading the Q2 FY27 Scorecard

Revenue for the quarter was ₹665 crore. EBITDA — earnings before interest, tax, depreciation and amortisation — came in at ₹186 crore, a 28.8% rise over the same quarter last year, working out to a 27.9% margin.

Profit after tax rose 55.8% year on year to ₹57 crore, with a PAT margin of 8.5%. The distance between a 28% operating margin and an 8.5% net margin is not a warning sign in itself. It is simply what an asset-heavy hospital business looks like once depreciation, interest and tax take their share.

Run the disclosed growth rates backwards and last year's EBITDA works out to roughly ₹144 crore, with year-ago PAT at about ₹37 crore. That is arithmetic, not a company disclosure — but it explains why a 28.8% operating gain produced a 55.8% jump in net profit. The base was small enough for the leverage to show.

Why the 27.9% Operating Margin Matters More Than the 55.8% Profit Jump

Eye care is one of the few medical specialties where volume economics actually work. Cataract and refractive surgeries are largely day-care procedures. Patients do not occupy beds for days. The expensive part — the phacoemulsification machine, the operating theatre, the diagnostic equipment — gets sweated across far more cases than in a multi-specialty hospital.

That is why 27.9% is the number to watch, not 55.8%. Percentage growth off a small base can be flattered by a single strong quarter. A margin approaching 28% has to be earned operationally, again and again, across hundreds of centres.

It also tells you something about pricing discipline. Eye-care chains sit in a segment where patients compare costs before booking surgery, so margin expansion usually comes from throughput and cost control rather than steep price increases.

From ₹186 Crore EBITDA to ₹57 Crore PAT — Where the ₹129 Crore Goes

Roughly ₹129 crore separates operating profit from net profit. In a hospital network, that gap is mostly three things: depreciation on medical equipment and leasehold improvements, finance costs — including interest on lease liabilities for rented premises under current accounting standards — and tax.

The practical takeaway is blunt. An 8.5% net margin means the business is profitable but not cushioned. A moderate rise in rentals, equipment costs or borrowing costs can compress that number faster than most investors expect.

It also explains why hospital chains are so focused on utilisation. Every additional surgery performed in an existing theatre adds revenue while adding very little cost — and almost all of it flows past the depreciation line.

The Moat: Scale, Surgeon Density and a Brand Patients Already Trust

Dr Agarwal's is a Chennai-headquartered chain built over decades by ophthalmologist Dr Amar Agarwal, and it now runs one of the larger networks of eye hospitals under a single brand in India. What makes that structure valuable is not the buildings — it is what sits inside them.

Specialist surgeons are the scarcest input in Indian eye care. A chain that can offer a young ophthalmologist high surgical volume, modern equipment and a clear career path retains talent that standalone clinics struggle to hold. High volume then feeds better outcomes, which feeds referral flow, which feeds more volume.

Add a brand that patients recognise before they book, and you get a referral engine that a new entrant cannot buy quickly. That is the moat — not technology, but trained people, throughput and trust compounding together.

Who Actually Feels This Result — Patients, Investors and Staff

For patients, an earnings release changes nothing on the day of surgery. But it does shape what comes next. Chains that generate free cash tend to expand into smaller cities, where specialised eye care is still thin on the ground. Chains that do not, slow down.

For investors, the pressure point is the bottom line. A listed hospital business is judged on PAT and return ratios, and an 8.5% margin leaves limited room for slippage. Minority shareholders will want to see whether the margin holds across the next two quarters, not just this one.

For staff, particularly surgeons and optometrists, strong operating margins are what fund equipment upgrades and training — the things that keep a clinical career attractive.

What the Filing Confirms and What It Does Not

Confirmed: revenue of ₹665 crore, EBITDA of ₹186 crore growing 28.8% year on year, an EBITDA margin of 27.9%, PAT of ₹57 crore growing 55.8%, and a PAT margin of 8.5%.

Not confirmed in the material reviewed: the revenue growth rate, same-store sales growth, city-wise or segment-wise performance, average revenue per patient, net debt, capex for the quarter, and any forward guidance. Readers looking for those details should check the company's exchange filing and investor presentation directly.

Anyone presenting revenue growth figures for this quarter without the company's own disclosure is estimating, not reporting. That distinction matters.

The Risks: Thin Net Margins, Heavy Capex and a Crowded Market

The first risk is structural. An 8.5% PAT margin gives little margin for error. If depreciation rises because new centres open, or interest costs climb on lease renewals, the bottom line moves disproportionately.

The second is competition. India's eye-care market is consolidating around a handful of organised chains, and several are aggressively adding centres in the same tier-2 and tier-3 cities. More players chasing the same patient pool can pressure pricing on high-volume procedures like cataract surgery.

The third is talent cost. Surgeons are expensive, and retention packages in a listed chain carry ESOPs and revenue-linked incentives that show up in operating costs.

The fourth is regulatory and public scrutiny. Private healthcare pricing remains a politically sensitive subject, and any policy move on procedure rates or insurance empanelment would affect the whole sector, not just one company.

The Wider Pattern — Private Eye Care Is Consolidating

This result is a data point in a much larger shift. For years, Indian eye care was delivered by standalone clinics and non-profit institutions. Over the past decade, organised chains have taken a growing share of a market driven by an ageing population, rising diabetes-related eye disease and greater willingness to pay for elective vision correction.

That shift favours operators with standardised protocols and capital to install modern equipment. It also means quarterly margins at the listed players are now watched as a proxy for the health of the entire sector — not just the individual company.

What Readers and Investors Should Do With These Numbers

If you are an investor, resist the 55.8% headline. Track three things over the next two quarters instead: whether the 27.9% EBITDA margin holds, whether revenue is growing in double digits, and whether net profit is rising because of operations or because of a lower tax or interest burden.

If you are a patient, nothing here changes your treatment decision. Cost, surgeon experience and outcomes remain the right filters — and most chains publish package pricing on request.

If you are a student or a professional tracking the healthcare sector, this result is a clean case study in operating leverage: how a small absolute change in operating profit produces a large percentage change in net profit when the base is low.

What Could Change by the Next Quarter

Two variables will decide how the next set of results reads. The first is whether the 27.9% margin is repeatable — a single quarter of strong throughput can flatter a margin, and the market will want confirmation.

The second is the cost line below EBITDA. If new centres are being added, depreciation and interest will rise first and revenue will follow later, which typically

Written by

Team HealthBiz